[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer].
Anthracyclines containing regimen are widely used in advanced breast cancer. The response to first line chemotherapy varies according to many individual factors and the theoretical response to a given protocol cannot predict the response of a patient. A randomized clinical trial (ERASME) was initiated in order to evaluate the more appropriate first line chemotherapy scheme in advanced breast cancer. Prognostic factors were included in a multiple logistic regression to explain the response after the first 3 chemotherapy courses (monthly FEC). Three factors were found to be statistically significant: adjuvant hormonotherapy, loco-regional metastases, adjuvant adriamycin containing regimen (pejorative prognostic factor). By combining these factors, this statistical model enables us to predict a response rate to a first line chemotherapy from 27 to 87%. Such a model can be taken into account in a decision-making procedure of first line chemotherapy in advanced breast cancer.
Chauvin
F
F
Unité de biostatistiques et d'évaluation des thérapeutiques, Centre Léon-Bérard, Lyon, France.
Magnet
M
M
Lasset
C
C
Catimel
G
G
Mayer
M
M
Chevarier
P
P
Jacquin
J P
JP
Peaud
P
P
Clavel
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012044:Regression Analysis
Etude des facteurs pronostiques de la réponse à une chimiothérapie de première ligne dans le cancer du sein en phase avancée. Groupe ERASME.